Portfolio · Project 13 · EU HTA · November 2026
EU JCA Tracker
Every Joint Clinical Assessment report published under the EU HTA Regulation, and how long each one took, stage by stage: from the developer’s first scope submission, through the PICO, the dossier, the draft report and patient and clinician input, to endorsement and publication. Each date comes from the report’s own procedural-steps table or the European Commission’s page for it.
At a glance
Since the regulation applied to cancer medicines and ATMPs on 12 January 2025.
—
—
—
Published JCA reports Newest first
| Published | Medicine | Indication | Type | Assessor · co-assessor | EU authorisation | HTACG endorsed | PICOs |
|---|
How long each JCA took, stage by stage
One bar per report, from the developer’s scope submission (filed alongside the EMA marketing authorisation application) to publication. Hover or tap a segment for its dates. Dossier preparation took — days, close to the 100 days the rules allow.
Days per stage
Across all published reports
Calendar days. A stage a report doesn’t date separately is left out of that stage’s figures.
| Stage | Reports | Median | Range |
|---|
Against the rules
Two deadlines in the implementing regulation can be checked from published dates.
Process details
Scope size, dossier rounds, assessors’ requests for information, the JCA subgroup meetings that discussed stakeholder input, and who gave that input. — No report so far dates a PICO explanation meeting with the developer.
| Medicine | PICOs | Dossier versions | Requests for information | Subgroup meetings on input | Patients · carers | Clinical experts | Notes |
|---|
Milestone dates A dash means the report doesn’t give the date
| Medicine | Scope info submitted | Draft PICO to experts | Final PICO to developer | Dossier v0.1 | Commission confirms dossier | 1st draft to subgroup | Draft to experts & developer | Subgroup finalises | HTACG endorses | Commission review done | Published |
|---|
Pipeline and watch list
All JCAs started
The Commission’s count presented on 29 June 2026, the latest official tally. One more JCA was discontinued on 16 September 2026.
Watch list
Signals since the last published report. Unconfirmed items are not counted above.
| Date | Signal | Confirmed |
|---|
How to read the stages
Scoping to dossier
PICO scoping runs from the developer’s scope submission to the final assessment scope sent to the developer; the consolidated draft goes to patients and clinical experts first. Dossier preparation ends at dossier version 0.1, and validation ends when the Commission confirms the dossier is complete.
Drafting to input
Drafting ends when the assessors send the first draft to the JCA subgroup. Subgroup review ends when the revised draft goes to patients, clinical experts and the developer, all at once. The next stage ends when the subgroup finalises the report.
Endorsement to publication
The HTACG, the member states’ coordination group, endorses the report. The Commission then runs a procedural review and publishes the report, its summary, the developer’s dossier and the developer’s factual-accuracy comments.
Sources
13
- European Commission. Joint clinical assessments for medicinal products, and the JCA report listing. health.ec.europa.eu · JCA reports
- Member State Coordination Group on HTA. JCA report on tovorafenib (Ojemda), Section 1. Published 9 June 2026. health.ec.europa.eu
- Member State Coordination Group on HTA. JCA report on lurbinectedin (Zepzelca), Section 1. Published 8 July 2026. health.ec.europa.eu
- Member State Coordination Group on HTA. JCA report on tarlatamab (Imdylltra), Section 1. Published 8 July 2026. health.ec.europa.eu
- Member State Coordination Group on HTA. JCA report on onasemnogene abeparvovec (Itvisma), Section 1. Published 7 September 2026. health.ec.europa.eu
- European Commission. Commission publishes first Joint Clinical Assessment, 9 June 2026 (marketing authorisation of tovorafenib, 20 April 2026). health.ec.europa.eu
- European Commission. JCA reports on two new lung cancer medicines, 8 July 2026 (authorisation 29 May 2026). ec.europa.eu
- European Commission. JCA report on an advanced therapy for spinal muscular atrophy, 7 September 2026 (authorisation 30 June 2026). ec.europa.eu
- European Commission. Update on the HTA Regulation, EMA Industry Standing Group, 29 June 2026 (JCA counts). ema.europa.eu
- HTACG flash report, 16 September 2026 (one JCA discontinued). health.ec.europa.eu
- HTACG flash report, 22 October 2026. health.ec.europa.eu
- Commission Implementing Regulation (EU) 2024/1381 on joint clinical assessments of medicinal products: Article 12(2) (dossier within 100 days of the first request) and Recital 7 (reports endorsed no later than 30 days after the marketing authorisation decision). EUR-Lex
- European Commission. Joint clinical assessments, latest updates (medical devices selected, 6 October 2026). health.ec.europa.eu
Be curious, not judgmental.
Design inspired by Spencer Gabor and Dieter Rams’s ten principles of good design.
© 2026 Jigar Rajpura. All rights reserved. No part of this site may be reproduced, distributed or adapted without written permission, except as set out in the Terms of use.
DisclaimerPersonal project, not sponsored by or affiliated with any employer (current or former) or any university I attended; views are my own. Dates are compiled with AI assistance from public European Commission documents and checked against them, but errors may remain, so rely on the linked reports. Nothing here comments on the medicines themselves. Full disclaimer